New Approach for Treatment of Primary Liver Tumors: The Role of Quercetin

References

• Goodman ZD: Neoplasms of the liver. Mod Pathol 20, Suppl 1, S49–S60, 2007.
   PubMed Web of Science ®Google Scholar
• Yu MC and Yuan JM: Environmental factors and risk for hepatocellular carcinoma. Gastroenterology 127, S72–S78, 2004.
   PubMed Web of Science ®Google Scholar
• Venook AP, Papandreou C, Furuse J, and de Guevara LL: The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist 15 Suppl 4, 5–13, 2010.
   PubMed Web of Science ®Google Scholar
• Yang JD and Roberts LR: Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol 7, 448–458, 2010.
   PubMed Web of Science ®Google Scholar
• Schütte K, Bornschein J, and Malfertheiner P: Hepatocellular carcinoma—Epidemiological trends and risk factors. Dig Dis 27, 80–92, 2009.
   PubMed Web of Science ®Google Scholar
• GLOBOCAN: Estimated Cancer Incidence, Mortality and Prevalende Worldwide in 2012. Available from: http://globocan.iarc.fr/Default.aspx. Accessed March 2015.
   Google Scholar
• El-Serag HB and Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132(7), 2557–2576, 2007.
   PubMed Web of Science ®Google Scholar
• Brito AF, Mendes M, Abrantes AM, Tralhão JG, and Botelho MF: Positron emission tomography diagnostic imaging in multidrug-resistant hepatocellular carcinoma: focus on 2-Deoxy-2-(18F)Fluoro-D-Glucose. Mol Diagn Ther 18(5), 495–504, 2014.
   PubMed Web of Science ®Google Scholar
• Villanueva A and Llovet JL: Targeted therapies for hepatocellular carcinoma. Gastroenterology 140, 1410–1426, 2011.
   PubMed Web of Science ®Google Scholar
• Wörns MA Weinmann A, Schuchmann M, and Galle PR: Systemic therapies in hepatocellular carcinoma. Dig Dis 27(2), 175–188, 2009.
   PubMed Web of Science ®Google Scholar
• Bruix J and Sherman M: Management of hepatocellular carcinoma. Hepatology 42, 1208–1236, 2005.
   PubMed Web of Science ®Google Scholar
• Bruix J and Sherman M: Management of hepatocellular carcinoma: an update. Hepatology 53, 1020–1022, 2011.
   PubMed Web of Science ®Google Scholar
• Bruix J, Boix L, Sala M, and Llovet JM: Focus on hepatocellular carcinoma. Cancer Cell 5, 215–9, 2004.
   PubMed Web of Science ®Google Scholar
• Ruff P: Therapeutic Options in Hepatocellular Carcinoma. Am J Cancer 3, 119–131, 2004.
   Google Scholar
• Johnson PJ: Systemic chemotherapy of liver tumors. Semin Surg Oncol 19, 116–24, 2000.
   PubMedGoogle Scholar
• Ma S, Jiao B, Liu X, Yi H, Kong D, et al.: Approach to radiation therapy in hepatocellular carcinoma. Cancer Treat Rev 36, 157–163, 2010.
   PubMed Web of Science ®Google Scholar
• Brito AF, Abrantes AM, Pinto-Costa C, Gomes AR, Mamede AC, et al.: Hepatocellular carcinoma and chemotherapy: the role of p53. Chemotherapy 58, 381–386, 2012.
   PubMed Web of Science ®Google Scholar
• Aljiffry M: Advances in diagnosis, treatment and palliation of cholangiocarcinoma, 1990–2009.
   Google Scholar
  World J Gastroenterol 15, 4240, 2009.
   PubMed Web of Science ®Google Scholar
• Blechacz B and Gores GJ. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology 48, 308–321, 2008.
   PubMed Web of Science ®Google Scholar
• Anderson CD, Pinson CW, Berlin J, and Chari RS: Diagnosis and Treatment of Cholangiocarcinoma. Oncologist 9, 43–57, 2004.
   PubMed Web of Science ®Google Scholar
• Amann T and Hellerbrand C: GLUT1 as a therapeutic target in hepatocellular carcinoma. Expert Opin Ther Targets 13, 1411–1427, 2009.
   PubMed Web of Science ®Google Scholar
• Amann T, Maegdefrau U, Hartmann A Agaimy A, Marienhagen J, et al.: GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis. Am J Pathol 174, 1544–1452, 2009.
   PubMed Web of Science ®Google Scholar
• Evans A, Bates V, Troy H, Hewitt S, Holbeck S, et al.: Glut-1 as a therapeutic target: increased chemoresistance and HIF-1-independent link with cell turnover is revealed through compare analysis and metabolomic studies. Cancer Chemother Pharmacol 61, 377–393, 2008.
   PubMed Web of Science ®Google Scholar
• Kubo Y, Aishima S, Tanaka Y, Shindo K, Mizuuchi Y, et al.: Different expression of glucose transporters in the progression of intrahepatic cholangiocarcinoma. Hum Pathol 45, 1610–1617, 2014.
   PubMed Web of Science ®Google Scholar
• Martin HJ, Kornmann F and Fuhrmann GF: The inhibitory effects of flavonoids and antiestrogens on the Glut1 glucose transporter in human erythrocytes. Chem Biol Interact 146:225–235. 2003.
   PubMed Web of Science ®Google Scholar
• Chen C, Zhou J, and Ji C: Quercetin: a potential drug to reverse multidrug resistance. Life Sci 87, 333–338, 2010.
   PubMed Web of Science ®Google Scholar
• Russo M, Spagnuolo C, Tedesco I, Bilotto S, and Russo GL: The flavonoid quercetin in disease prevention and therapy: facts and fancies. Biochem Pharmacol 83, 6–15, 2012.
   PubMed Web of Science ®Google Scholar
• Berndt K, Campanile C, Muff R, Strehler E, Born W, et al.: Evaluation of quercetin as a potential drug in osteosarcoma treatment. Anticancer Res 33, 1297–1306, 2013.
   PubMed Web of Science ®Google Scholar
• Vidya PR, Senthil MR, Maitreyi S, Ramalingam K, Karunagaran D, et al.: The flavonoid quercetin induces cell cycle arrest and mitochondria-mediated apoptosis in human cervical cancer (HeLa) cells through p53 induction and NF-κB inhibition. Eur J Pharmacol 649, 84–91, 2010.
   PubMed Web of Science ®Google Scholar
• Sudan S and Rupasinghe HPV. Quercetin-3-O-glucoside induces human DNA topoisomerase II inhibition, cell cycle arrest and apoptosis in hepatocellular carcinoma cells. Anticancer Res 34, 1691–9, 2014.
   PubMed Web of Science ®Google Scholar
• Vargas AJ, Sittadjody S, Thangasamy T, Mendoza EE, Limesand KH, et al.: Exploiting tyrosinase expression and activity in melanocytic tumors: quercetin and the central role of p53. Integr Cancer Ther 10, 328–40, 2011.
   PubMed Web of Science ®Google Scholar
• Wang G, Zhang J, Liu L, Sharma S, and Dong Q: Quercetin potentiates doxorubicin mediated antitumor effects against liver cancer through p53/Bcl-xl. PLoS One 7, e51764, 2012.
   PubMed Web of Science ®Google Scholar
• Chan ST, Yang NC, Huang CS, Liao JW, and Yeh SL: Quercetin enhances the antitumor activity of trichostatin A through upregulation of p53 protein expression in vitro and in vivo. PLoS One 8, e54255, 2013.
   PubMed Web of Science ®Google Scholar
• Brito AF, Abrantes AM, Ribeiro M, Oliveira R, Casalta-Lopes J, et al.: Fluorine-18 Fluorodeoxyglucose Uptake in Hepatocellular Carcinoma: correlation withGlucose Transporters and p53 Expression. J Clin Exp Hepatol 5, 183–189, 2015.
   PubMedGoogle Scholar
• Kaino M: Alterations in the tumor supressor genes p53, RB, p16/MTS1, and p15/MTS2 in human pancreatic cancer and hepatoma cell lines. J Gastroenterol 32, 40–46, 1997.
   PubMed Web of Science ®Google Scholar
• Jia LQ, Osada M, Ishioka C, Gamo M, Ikawa S, et al.: Screening the p53 status of human cell lines using a yeast functional assay. Mol Carcinog 19, 243–253, 1997.
   PubMed Web of Science ®Google Scholar
• Mamede AC, Laranjo M, Carvalho MJ, Abrantes AM, Pires AS, et al.: Effect of amniotic membrane proteins in human cancer cell lines: an exploratory study. J Membr Biol 247, 357–360, 2014.
   PubMed Web of Science ®Google Scholar
• Chou T and Talalayi P: Quantitative dose-effect relationshios: the combined effects of Multiple Drugs or Enzime Inhibitors. Adv Enzym Regul 22, 27–55, 1984.
   PubMedGoogle Scholar
• Mamede AC, Pires AS, Abrantes AM, Tavares SD, Gonçalves AC et al.: Cytotoxicity of ascorbic acid in a human colorectal adenocarcinoma cell line (WiDr): in vitro and in vivo studies. Nutr Cancer 64, 1049–1057, 2012.
   PubMed Web of Science ®Google Scholar
• Santos K, Laranjo M, Abrantes AM, Brito AF, Gonçalves C, et al.: Targeting triple-negative breast cancer cells with 6,7-bis(hydroxymethyl)-1H,3 H-pyrrolo[1,2-c]thiazoles. Eur J Med Chem 79, 273–281, 2014.
   PubMed Web of Science ®Google Scholar
• Casalta-lopes J, Abrantes AM, Laranjo M, Rio J, Gonçalves AC, et al.: Efflux Pumps Modulation in Colorectal Adenocarcinoma Cell Lines: the Role of Nuclear Medicine. J Cancer Ther 2, 408–417, 2011.
   Google Scholar
• Abrantes AM, Serra ME, Gonçalves AC, Rio J, Oliveiros B, et al.: Hypoxia-induced redox alterations and their correlation with and 99 m Tc-HL-91 uptake in colon cancer cells Tc-MIBI. Nucl Med Biol 37, 125–132, 2010.
   PubMed Web of Science ®Google Scholar
• Seufi AM, Ibrahim SS, Elmaghraby TK, and Hafez EE: Preventive effect of the flavonoid, quercetin, on hepatic cancer in rats via oxidant/antioxidant activity: molecular and histological evidences. J Exp Clin Cancer Res 28(1), 80, 2009.
   PubMed Web of Science ®Google Scholar
• Chang YF, Hsu YC, Hung HF, Lee HJ, Lui WY, et al.: Quercetin induces oxidative stress and potentiates the apoptotic action of 2-methoxyestradiol in human hepatoma cells. Nutr Cancer 61, 735–745, 2009.
   PubMed Web of Science ®Google Scholar
• Shi M, Wang FS, and Wu ZZ. Synergetic anticancer effect of combined quercetin and recombinant adenoviral vector expressing human wild-type p53, GM-CSF and B7-1 genes on hepatocellular carcinoma cells in vitro. World J Gastroenterol 9, 73–78, 2003.
   PubMed Web of Science ®Google Scholar
• Angst E, Park JL, Moro A, Lu QY, Lu X, et al.: The flavonoid quercetin inhibits pancreatic cancer growth in vitro and in vivo. Pancreas 42(2), 223–229, 2014.
   Web of Science ®Google Scholar
• Kudo M, Naito Z, Yokoyama M, and Asano G: Effects of quercetin and sunphenon on responses of cancer cells to heat shock damage. Exp Mol Pathol 66, 66–75, 1999.
   PubMed Web of Science ®Google Scholar
• Yeh YA, Herenyiova M, and Weber G: Quercetin: synergistic action with carboxyamidotriazole in human breast carcinoma cells. Life Sci 57(13), 1995.
   PubMed Web of Science ®Google Scholar
• Shen F and Weber G: Synergistic action of quercetin and genistein in human ovarian carcinoma cells. Oncol Res 9, 597–602, 1997.
   PubMed Web of Science ®Google Scholar
• Jakubowicz-gil J, Langner E, and Dorota B: Apoptosis induction in human glioblastoma multiforme T98G cells upon temozolomide and quercetin treatment. Tumor Biol 34(4), 2367–2378, 2013.
   PubMed Web of Science ®Google Scholar
• Bishayee K, Ghosh S, Mukherjee A, Sadhukhan R, Mondal J, et al.: Quercetin induces cytochrome-c release and ROS accumulation to promote apoptosis and arrest the cell cycle in G2/M, in cervical carcinoma: signal cascade and drug-DNA interaction. Cell Prolif 46, 153–163, 2013.
   PubMed Web of Science ®Google Scholar
• Volate SR, Davenport DM, Muga SJ, and Wargovich MJ: Modulation of aberrant crypt foci and apoptosis by dietary herbal supplements (quercetin, curcumin, silymarin, ginseng and rutin). Carcinogenesis 26, 1450–1456, 2005.
   PubMed Web of Science ®Google Scholar
• Gao X, Wang B, Wei X, Men K, Zheng F, et al.: Anticancer effect and mechanism of polymer micelle-encapsulated quercetin on ovarian cancer. Nanoscale 4, 7021–7030, 2012.
   PubMed Web of Science ®Google Scholar
• Ozaki T and Nakagawara A: p73, a sophisticated p53 family member in the cancer world. Cancer Sci 96, 729–737, 2005.
   PubMed Web of Science ®Google Scholar
• Roos WP and Kaina B: DNA damage-induced cell death by apoptosis. Trends Mol Med 12(9), 440–450. 2006.
   PubMed Web of Science ®Google Scholar
• Chien SY, Wu YC, Chung JG, Yang JS, Lu HF, et al.: Quercetin-induced apoptosis acts through mitochondrial- and caspase-3-dependent pathways in human breast cancer MDA-MB-231 cells. Hum Exp Toxicol 28, 493–503, 2009.
   PubMed Web of Science ®Google Scholar
• Chen S, Nien S, Wu C,Liu CL, Chang YC, et al.: Reappraisal of the anticancer efficacy of quercetin in oral cancer cells. J Chinese Med Assoc 76, 146–152, 2013.
   PubMed Web of Science ®Google Scholar
• Gokbulut AA, Apohan E, and Baran Y: Resveratrol and quercetin-induced apoptosis of human 232B4 chronic lymphocytic leukemia cells by activation of caspase-3 and cell cycle arrest. Hematology 18, 144–150, 2013.
   PubMed Web of Science ®Google Scholar
• Vera JC, Reyes AM, Velásquez FV, Rivas CI, Zhang RH, et al.: Direct inhibition of the hexose transporter GLUT1 by tyrosine kinase inhibitors. Biochemistry 40, 777–790, 2001.
   PubMed Web of Science ®Google Scholar
• Rabkin Z, Israel O, and Keidar Z: Do hyperglycemia and diabetes affect the incidence of false-negative 18F-FDG PET/CT studies in patients evaluated for infection or inflammation and cancer? A Comparative analysis. J Nucl Med 51, 1015–1020, 2010.
   PubMed Web of Science ®Google Scholar
• Jadvar H, Alavi A, and Gambhir SS: 18F-FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterization. J Nucl Med 50, 1820–1827, 2009.
   PubMed Web of Science ®Google Scholar
• Suzawa N, Ito M, Qiao S, Uchida K, Takao M, et al.: Assessment of factors influencing FDG uptake in non-small cell lung cancer on PET/CT by investigating histological differences in expression of glucose transporters 1 and 3 and tumour size. Lung Cancer 72, 191–198, 2011.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al.: Sorafenib in Advanced Hepatocellular Carcinoma. N Engl J Med 359, 378–390, 2008.
   PubMed Web of Science ®Google Scholar
• Noel MS and Hezel AF: New and emerging treatment options for biliary tract cancer. Onco Targets Ther 6, 1545–1552, 2013.
   PubMed Web of Science ®Google Scholar
• Huether A, Höpfner M, Baradari V, Schuppan D, and Scherübl H: Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma. Biochem Pharmacol 73, 1308–1317, 2007.
   PubMed Web of Science ®Google Scholar
• Ezzoukhry Z, Louandre C, Trécherel E, Godin C, Chauffert B, et al.: EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib. Int J Cancer 131, 2961–2969, 2012.
   PubMed Web of Science ®Google Scholar
• Jung JH, Lee JO, Kim JH, Lee SK, You GY, et al.: Quercetin suppresses HeLa cell viability via AMPK-induced HSP70 and EGFR down-regulation. J Cell Physiol 223, 408–414, 2010.
   PubMed Web of Science ®Google Scholar